

This material is an English translation of the press release announced on September 30, 2015 in Japanese, and the Japanese release is given priority about the content and the interpretation.

September 30, 2015

**Notice of Revision of Financial Forecast**

Hisamitsu Pharmaceutical Co., Inc., (Chairman and CEO: Hirotaka Nakatomi) announces, in light of the recent trend in our business performance, as follows, the revision of consolidated financial forecast for the second quarter (cumulative) of the fiscal year ending February 28, 2016, which had been released on April 8, 2015.

**1.Revision of Consolidated Financial Forecast for Second Quarter (Cumulative)**

Revised Consolidated Financial Forecast for Second Quarter (Cumulative) of Fiscal Year Ending February 28, 2016

(March 1, 2015, through August 31, 2015)

(Amounts in millions of yen, except amounts per share in yen)

	Net Sales	Operating Income	Ordinary Income	Quarterly Net Income	Quarterly Net Income per Share
Previous Forecast (A)	83,300	12,700	13,000	8,500	99.22 yen
<b>Revised Forecast (B)</b>	<b>82,400</b>	<b>14,500</b>	<b>14,600</b>	<b>9,400</b>	<b>109.72 yen</b>
Variance in Amount (B-A)	△ 900	+ 1,800	+ 1,600	+ 900	
Variance in Percentage (%)	△ 1.1%	+ 14.2%	+ 12.3%	+ 10.6%	
*Ref. Second Quarter Results of Prior Fiscal Year (Second Quarter of Fiscal Year Ended February 28, 2013)	77,052	10,355	15,572	9,574	111.76 yen

**2. Reasons for the Revision**

The reason for revising the consolidated financial forecast for second quarter (cumulative) of fiscal year ending February 28, 2016 is that the operating income, ordinary income, and quarterly net income for the said quarter are expected to exceed the figures contained in the previous forecast (A) due to the deferral of the unused research expense (as selling, general and administrative expenses) by Hisamitsu, non-consolidated, to the third quarter onwards. As a result, the figures were revised as shown in the revised forecast (B).

**3. Consolidated Full Year Financial Forecast for Fiscal Year Ending February 28, 2014**

At this juncture, there is no change in the consolidated full-year financial forecasts for the fiscal year ending February 28, 2016. Depending on progress in the implementation of measures to promote the sales of our major products, if it becomes necessary for us to revise the consolidated full-year financial forecasts for the fiscal year ending February 28, 2016, we will promptly disclose the revisions.

**4. Dividends**

At this juncture, there is no change in our plan for the payment of interim and year-end dividends.

\* The financial forecasts described above are prepared on the basis of information available as of the date of this announcement. Actual financial results may differ from those included in these financial forecasts due to a variety of factors going forward.